Figure 2.
PK and pharmacodynamics monitoring. (A) PK analyses showed detectable F-652 levels at 8 hours, 72 hours, and 7 days following the first and last doses of the rhIL-22 dimer. (B) Measurement of C-reactive protein (CRP) levels prior to administering F-652 and 3 days after administration. F-652 was administered on stay days 0 (dose 1), 7 (dose 2), 14 (dose 3), and 21 (dose 4). ∗P < .05, ∗∗P < .01.

PK and pharmacodynamics monitoring. (A) PK analyses showed detectable F-652 levels at 8 hours, 72 hours, and 7 days following the first and last doses of the rhIL-22 dimer. (B) Measurement of C-reactive protein (CRP) levels prior to administering F-652 and 3 days after administration. F-652 was administered on stay days 0 (dose 1), 7 (dose 2), 14 (dose 3), and 21 (dose 4). ∗P < .05, ∗∗P < .01.

Close Modal

or Create an Account

Close Modal
Close Modal